Biosenic (CHIX:BIOSB) Stock Based Compensation: €-0.06 Mil (TTM As of Dec. 2024)


CHIX:BIOSB Biosenic CHIX:BIOSB
9 GF Score
Price €2.60
View Full Analysis

What is Biosenic Stock Based Compensation?

Biosenic CHIX:BIOSB 9 Stock Based Compensation is €-0.06 Mil as of Dec. 2024. GuruFocus rates CHIX:BIOSB with a GF Score™ of 9/100.

Biosenic's Stock Based Compensation for the six months ended in Dec. 2024 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06 Mil.

Biosenic Stock Based Compensation Related Terms

Biosenic Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Biosenic's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosenic Stock Based Compensation Chart

Biosenic Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 -0.10 0.00 0.00 0.00

Biosenic Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.06 0.00
CHIX:BIOSB
9GF Score
Biosenic CHIX:BIOSB
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosenic Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.06 Mil.

What does a Stock Based Compensation of €-0.06 Mil mean?
Biosenic (CHIX:BIOSB) has a Stock Based Compensation of €-0.06 Mil as of Dec. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Biosenic and its competitors.
Is Biosenic's Stock Based Compensation too high?
Biosenic's current Stock Based Compensation is €-0.06 Mil. Overall, Biosenic has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Biosenic's Stock Based Compensation compare to VRTX and REGN?
Biosenic's Stock Based Compensation of €-0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Biosenic and its competitors. Biosenic's current Stock Based Compensation is €-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosenic stock overvalued right now?
Biosenic (CHIX:BIOSB) has a current Stock Based Compensation of €-0.06 Mil. The current Stock Based Compensation is €-0.06 Mil. Biosenic's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Biosenic (CHIX:BIOSB), the current Stock Based Compensation is €-0.06 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosenic Business Description

Address Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.
9GF Score

Get the complete analysis for CHIX:BIOSB

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price